Warren Buffett divided the investment universe into Inevitables, Highly Probables, and Impostors. The Inevitables are companies whose domin...

Investors are increasingly betting that “China is back” as the economy rebounds from years of deflation, helped by strong manufacturing, ex...

Flipkart has hit pause on its IPO in a jittery market. This and more in today's ETtech Top 5.

Odyssey Therapeutics debuted on Nasdaq with an 11.1% surge, reaching a $899.9 million valuation. The autoimmune disease specialist successf...

Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...

US stock market today: Why Dow Jones Industrial Average falls while S&P 500 and Nasdaq Composite hold steady? US stock market today shows a...

US stock market crashes today: why Dow Jones, S&P 500 and Nasdaq are down today? Wall Street turns red as gold and silver prices also slip....

Windlas Biotech approved a Rs 47 crore share buyback at Rs 1,000 per share via the tender route, with April 24 set as the record date. The ...

Four companies—Wipro, Cyient, Windlas Biotech, and Aurobindo Pharma—are set to announce or act on share buybacks this month, with Aurobindo...

In the Nifty50 index, 29 stocks were trading in the green, while 21 stocks were in the red.

Concord Biotech shares fell 16% to Rs 1,777.7 after the company reported a 2.1% YoY decline in Q3 FY25 net profit to Rs 75.92 crore, despit...

Rossari Biotech Ltd., incorporated in the year 2009, is a Small Cap company (having a market cap of Rs 4501.56 Crore) operating in Chemical...

Concord Biotech is a biotechnology company and a leading maker of select fermentation-based APIs across immunosuppressants and oncology in ...

Shares of Rossari Biotech have risen over 11% in the last three trading sessions, following the company's Annual General Meeting on May 31,...

Prime Minister Narendra Modi will be visiting vaccine maker Bharat Biotech's facility here on Saturday as part of his three-city tour to ta...

According to Nasdaq, the stock price of ISIS Pharmaceuticals crossed above its 200-day moving average for the first time since early spring.

ISIS Pharmaceuticals, a $4.3 billion biotech firm surged 10% today, and it's up 43% in the last three months.